Log on / register
Feedback | Support | My details
Open AccessResearch article

Developments in esophageal surgery for adenocarcinoma: a comparison of two decades

I Gockel email, FS Sultanov email, M Domeyer email, U Goenner email and Th Junginger email

Department of General and Abdominal Surgery, Johannes Gutenberg-University of Mainz, Mainz, Germany

author email corresponding author email

BMC Cancer 2007, 7:114doi:10.1186/1471-2407-7-114

Published: 29 June 2007

Abstract

Background

The objective of this study was to examine outcomes in patients undergoing esophageal resection for adenocarcinoma at our institution during a 20-year period and, in particular, to address temporal trends in long-term survival.

Methods

Out of 470 patients who underwent esophagectomy for malignancy between September 1985 and September 2005, a total number of 175 patients presented with esophageal adenocarcinoma. Patients enrolled in this study included AEG (adenocarcinoma of the esophagogastric junction) type I tumors only. Time trends were studied comparing two decades, 9/1985 to 9/1995 (DI) and 10/1995 to 9/2005 (DII).

Results

The overall survival was significantly more favourable in patients undergoing esophageal resection for adenocarcinoma in the recent time period (DII, 10/1995 to 9/2005) as compared to the early time period (DI, 9/1985 to 9/1995) (log rank test: p = 0.0329). Significant differences in the recent decade were seen based on lower ASA-classifications, earlier tumor stages, and the operative procedure with a higher frequency of transhiatal resections (p < 0.05). 30-day mortality improved from 8.3% to 3.1% during the 20-year time-interval, thus without statistical significance.

Conclusion

Based on our experience, overall survival is improving over time for adenocarcinoma of the esophagus. Factors that may play an important role in this trend include early diagnosis and improved patient selection through better preoperative staging, improved surgical technique with a tailored approach carefully evaluated by physiologic patient status, comorbidity and tumor extent.


© 1999-2010 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.